“…However, relatively few studies have been performed so far, yielding conflicting results. The aim of this exploratory study was to investigate whether the above-mentioned alterations in TRP metabolism, which in part were elucidated by our former retrospective studies [10,11] , indeed occur in a prospective trial during IFN-␣ treatment in oncology patients, and if so, whether these changes are associated with emerging psychiatric symptoms and syndromes using regular psychiatric assessments combining clinical judgment, standardized diagnosis, observer-based rating scales and self-report questionnaires. Since there are two types of IFN-␣ , conventional and pegylated (PEG) IFN-␣ , that are both widely used, alter TRP metabolism equally and can lead to a comparable extent and frequency of depressive symptoms [10,11,14,15] , patients treated with either one of these types of IFN-␣ were allowed to be accrued.…”